FDA Advisory Committee Votes in Favor of Abbott’s First-of-Its-Kind TriClip™ System to Treat People With a Leaky Tricuspid Heart Valve
Abbott (NYSE: ABT) today announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the U.S. Food and Drug Administration (FDA) confirmed 13 to 1, with 0 abstention that the benefits of Abbott’s TriClip™ transcatheter edge-to-edge repair…
Abbott Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms
Abbott (NYSE: ABT) today announced the first global procedures have been conducted using the company’s new Volt™ Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heart rhythms such as atrial fibrillation (AFib). Over 30 patients were recently treated…
